Inclisiran for the treatment of hypercholesterolaemia

Joel C Marrs, Sarah L Anderson

Article Type

Review

Published

This narrative review presents and examines current evidence regarding the use of inclisiran for the treatment of hyperlipidaemia and its potential role to reduce cardiovascular events.

Read more

Risk of gastrointestinal bleeding in Asian patients receiving oral anticoagulants for stroke prevention in atrial fibrillation

Alejandro Bimbo Diaz, Jeremy Chow, Fan Kee Hoo, Gary Lee Chin Keong, Narayanaswamy Venketasubramanian, Nannette Rey, Gregorio Rogelio, Radhika Mehta

Article Type

Meeting Report

Published

The Menarini Asia Pacific Advancing Patient care with EdoXaban (APEX) 2023 Expert Meeting convened in Kuala Lumpur, Malaysia, and provided a forum for experts to explore the occurrence of gastrointestinal bleeding linked to non-vitamin K antagonist oral anticoagulants in Asian clinical practice for stroke prevention in atrial fibrillation. This report amalgamates insights from two segments of the meeting.

Read more

A UK multicentre audit of the management of patients with primary hypercholesterolaemia or mixed dyslipidaemia with bempedoic acid against published lipid-lowering treatment targets

Sudarshan Ramachandran, Amro Maarouf, Karen Mitchell, Tony Avades, Peter Smith, Lee Boulton, Jennifer Kelly, Nitasha Vekaria, Elizabeth Hughes

Article Type

Original Research

Published

This retrospective multicentre audit aimed to evaluate the achievement of lipid-lowering targets with bempedoic acid in UK patients based on recommendations in the Joint British Societies (JBS) guidelines for the prevention of cardiovascular disease.

Read more

Corrigendum: Vulnerable period in heart failure: a window of opportunity for the optimization of treatment – a statement by Mexican experts

José Antonio Magaña Serrano, José Angel Cigarroa López, Adolfo Chávez Mendoza, Juan Betuel Ivey-Miranda, Genaro Hiram Mendoza Zavala, Luis Olmos Domínguez, Sergio Armando Chávez Leal, José Ernesto Pombo Bartelt, Eduardo Heberto Herrera-Garza, Gerardo Mercado Leal, Rodolfo Parra Michel, Luisa Fernanda Aguilera Mora, Patricia Lenny Nuriulu Escobar

Article Type

Corrigendum

Published

The authors wish to make the following corrections to their article: Magaña Serrano JA, Cigarroa López JA, Chávez Mendoza A, Ivey-Miranda JB, Mendoza Zavala GH, Olmos Domínguez L, Chávez Leal SA, Pombo Bartelt JE, Herrera-Garza EH, Mercado Leal G, Parra Michel R, Aguilera Mora LF, Nuriulu Escobar PL. Corrigendum: Vulnerable period in heart failure: a window of opportunity for the optimization of treatment – a statement by Mexican experts. Drugs Context. 2024;13:2023-8-1. https://doi.org/10.7573/dic.2023-8-1

Read more

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.